All In Biotech

Drug Trial Radar · NCT07460986

A Phase Ib/II Study to Evaluate Safety and Efficacy of Bexmarilimab in Combination With Doxorubicin in Metastatic Soft-tissue Sarcoma.

Last checked: Nov 19, 2026Latest source record: Aug 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 278 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

278

Planned (sponsor's estimate)

Start

Aug 20, 2026

Primary completion

Jul 2028

Study completion Oct 2028

Sponsor

Lead sponsor
MedSIRAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Faron Pharmaceuticals Ltd
First posted
Mar 10, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial will Study a type of sarcoma defined metastatic soft-tissue sarcoma (STS). Participants will be treated with bexmarilimab, a CLEVER-1 antibody plus doxorubicin, a chemotherapy. The main purpose of the Study is to analyze the safety (to find out how safe or toxic a treatment is to appropriately manage the risks) and efficacy (to find out how effective a treatment is) of bexmarilimab combined with doxorubicin in participants who have STS.

Conditions

  • Soft Tissue Sarcoma (STS)

Interventions

  • bexmarilimabDrug

    RP2D of bexmarilimab administered as IV infusion on D1 of 21-day cycle for 6 cycles.

  • DoxorubicinDrug

    75 mg/m2 doxorubicin administered as IV infusion on D1 of 21-day cycle for 6 cycles.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase Ib: MTD and RP2DTime frame: Up to 14 months
  2. Phase II: PFSTime frame: Up to 36 months

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • Institut Català d' Oncologia Badalona (ICO)

    Badalona, Spain · Not yet recruiting

  • Hospital de Cruces

    Barakaldo, Spain · Not yet recruiting

  • Hospital Universitari Vall D'Hebron (VHIO)

    Barcelona, Spain · Recruiting

  • Hospital Clínico San Carlos

    Madrid, Spain · Recruiting

  • Hospital Universitario Doce de Octubre

    Madrid, Spain · Recruiting

  • Hospital Universitario Gregorio Marañón

    Madrid, Spain · Not yet recruiting

  • Hospital Universitario La Paz

    Madrid, Spain · Not yet recruiting

  • Hospital Universitario Virgen de la Victoria

    Málaga, Spain · Recruiting

  • Hospital Universitario de Canarias

    San Cristóbal de La Laguna, Spain · Not yet recruiting

  • Hospital Universitario Virgen del Rocío

    Seville, Spain · Not yet recruiting

  • Hospital Universitario Miguel Servet

    Zaragoza, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.